Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT02414269 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02414269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02414269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 31, 2015
Completion date
April 30, 2027
Enrollment
113 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, malignant pleural disease, mesothelioma, metastases